Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 5.07 is in line with its 5-year average of 5.54, near the low end of its 5-year range (3.82–10.17).
As of the fiscal period ended Tuesday, June 30, 2026. 1.64% above its 12-month average of 4.99.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.07.
QUICK RATIO (ACID-TEST)
5.07
QUICK RATIO (ACID-TEST) AVG TTM
4.99
QUICK RATIO (ACID-TEST) AVG 3Y
5.04
QUICK RATIO (ACID-TEST) AVG 5Y
5.54
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.64%
CURRENT VS 3Y AVG
+0.61%
CURRENT VS 5Y AVG
-8.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 529 covered companies
CURRENT VS SECTOR MEDIAN
+69.48%
vs the sector median at left
Inhibrx Biosciences Inc.
Market Cap
$1.40B
Quick Ratio (Acid-Test)
5.07
TTM Avg
4.99
3Y Avg
5.04
5Y Avg
5.54
Market Cap
$1.40B
Quick Ratio (Acid-Test)
11.11
TTM Avg
12.01
3Y Avg
12.01
5Y Avg
12.01
Market Cap
$1.38B
Quick Ratio (Acid-Test)
35.85
TTM Avg
18.03
3Y Avg
18.03
5Y Avg
18.03
Market Cap
$1.43B
Quick Ratio (Acid-Test)
5.61
TTM Avg
9.29
3Y Avg
11.65
5Y Avg
16.84
Market Cap
$1.36B
Quick Ratio (Acid-Test)
11.09
TTM Avg
7.43
3Y Avg
12.87
5Y Avg
13.91
Market Cap
$1.47B
Quick Ratio (Acid-Test)
2.94
TTM Avg
3.04
3Y Avg
2.84
5Y Avg
2.90
Market Cap
$1.47B
Quick Ratio (Acid-Test)
18.31
TTM Avg
12.63
3Y Avg
8.12
5Y Avg
8.12
Market Cap
$1.48B
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.33B
Quick Ratio (Acid-Test)
14.16
TTM Avg
12.98
3Y Avg
15.39
5Y Avg
17.04
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.40B | 5.07 | 4.99 | 5.04 | 5.54 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 11.11 | 12.01 | 12.01 | 12.01 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.38B | 35.85 | 18.03 | 18.03 | 18.03 |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 5.61 | 9.29 | 11.65 | 16.84 |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.36B | 11.09 | 7.43 | 12.87 | 13.91 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 2.94 | 3.04 | 2.84 | 2.90 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.47B | 18.31 | 12.63 | 8.12 | 8.12 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.48B | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | 14.16 | 12.98 | 15.39 | 17.04 |
| GH Research PLC (GHRS)vs › | $1.51B | 28.70 | 25.68 | 28.23 | 39.61 |
Quick Ratio
5.07
Excludes inventory
Current Ratio
5.07
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 5.07 |
| 2026-03-31 | 6.46 |
| 2025-12-31 | 3.93 |
| 2025-09-30 | 4.49 |
| 2025-06-30 | 4.98 |
| 2025-03-31 | 5.12 |
| 2024-12-31 | 3.94 |
| 2024-09-30 | 4.70 |
| 2024-06-30 | 6.20 |
| 2024-03-31 | 3.82 |
| 2023-12-31 | 5.25 |
| 2023-09-30 | 10.17 |
| 2023-06-30 | 6.49 |
| 2023-03-31 | 7.48 |
| 2022-12-31 | 10.17 |
| 2022-09-30 | 6.06 |
| 2022-06-30 | 7.50 |
| 2022-03-31 | 7.19 |
| 2021-12-31 | 6.23 |
| 2021-09-30 | 4.53 |
| 2021-06-30 | 5.85 |
| 2021-03-31 | 3.91 |
| 2020-12-31 | 8.33 |
| 2020-09-30 | 3.82 |
| 2020-06-30 | 0.20 |
| 2020-03-31 | 0.13 |
| 2019-12-31 | 0.60 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 2.19 |
| 2019-03-31 | 0.47 |
| 2018-12-31 | 0.21 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 1.62 |
